Clinical Characteristics of Infantile Hemangioma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-06

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to identify the clinical characteristics of infantile hemangioma (IH) in our single center in China. The second objective of the study is to identify the clinical features of infantile hepatic hemangioma (IHH) and ulceration in patients with IHs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China

NCT03173352

Infantile Hemangioma Capillary Hemangioma Capillary Hemangiomas +2 more

UNKNOWN

Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas

NCT00374335

Hemangioma

COMPLETED NA

Optical Tomographic Imaging of Infantile Hemangiomas

NCT01673971

Infantile Hemangioma

COMPLETED

Infantile Hemangioma With Minimal or Arrested Growth : Epidemiology, Clinical Characteristics and Evolution

NCT05080868

Hemangioma, Capillary

COMPLETED

Ontogeny of Infantile Hemangiomas With Skin Imaging Modalities

NCT02061735

Infantile Hemangiomas

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Infantile hemangioma (IH) is the most common benign tumor of infancy with an estimated prevalence of 4%-5%. IHs may be presented in any part of body including the visceral organs, but are preferentially located on the face, head and neck area. IHs exhibit a characteristic life cycle consisting of a rapid proliferating phase within the first year of life followed by a slowly involuted phase lasting for up to five years. Although most resolve over time without major sequelae, a significant subset can result in severe complications including disfiguring and ulceration, some even could impair organ functions and threaten patients' life. Risk factors of IHs have been identified including multiple gestation, low birth weight, prematurity, white race, eclampsia and placental abnormalities. However, the exact occurrence, clinical features and risk factors of IHs is still unknown in Chinese patients because of the lack of large scale of prospective studies. In addition, characteristics of ulceration of IHs and infantile hepatic hemangiomas (IHHs) are also not well documented. Therefore, it's important to perform this prospective study to determine the clinical features of Chinese patients with IHs, and this study will also make contributions to the prevents, diagnoses and treatments of IHs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemangioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≤6 years old
* Diagnose of IHs
* Consent of both parents (or the person having parental authority in families)

Exclusion Criteria

* Congenital hemangioma, kaposiform hemangioendothelioma, or other vascular anomalies
* Age\>6 years
* Hemangioma has been previous treated with corticosteroids, laser, cryotherapy, or only other treatments
* Patients with an inability to participate or to follow the study treatment and assessment plan

Maximum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No